Последние добавленные видео:
BCMA-naive
-
2 года назад
279 2 года назад 3:25Outcomes of patients who are BCMA-exposed versus BCMA-naïve in penta-R/R myeloma
-
3 года назад
74 3 года назад 2:11Outcomes of BCMA-exposed vs BCMA-naïve patients with R/R multiple myeloma
-
3 года назад
490 3 года назад 6:07MagnetisMM-3: elranatamab in R/R multiple myeloma naive to BCMA-directed therapy
-
2 года назад
325 2 года назад 7:04Safety and efficacy of elranatamab in RRMM & prior BCMA therapies: Analysis from MagnetisMM studies
-
3 года назад
119 3 года назад 1:38Using BCMA-targeting agents in earlier lines of treatment for multiple myeloma
-
2 года назад
707 2 года назад 2:14What is BCMA Directed therapy? #myeloma
-
4 года назад
139 4 года назад 1:40Overcoming BCMA loss in myeloma cells
-
2 года назад
177 2 года назад 1:10The importance of BCMA, FcRH5 and GPRC5D in multiple myeloma
-
1 год назад
74 1 год назад 2:28Pre-apheresis prediction of toxicity & response to BCMA-directed CAR-T in patients with R/R myeloma
-
5 месяцев назад
56 5 месяцев назад 1:31Managing toxicities associated with BCMA-targeting bispecific antibodies in multiple myeloma
-
2 года назад
162 2 года назад 1:48Mechanisms behind the loss of BCMA in multiple myeloma & options for patients
-
1 месяц назад
138 1 месяц назад 1:43Activity of the FcRH5 bispecific antibody cevostamab after prior BCMA therapy in multiple myeloma
-
6 лет назад
149 6 лет назад 1:56Serum BCMA: a new prognostic marker for PFS in myeloma
-
2 года назад
12 2 года назад 5:03Elranatamab shows efficacy in patients with RRMM with prior BCMA-directed therapies
-
5 месяцев назад
44 5 месяцев назад 1:12The transformative impact of BCMA-targeting bispecific antibodies in RRMM
-
2 года назад
565 2 года назад 1:20:14Betting on BCMA Therapy in Multiple Myeloma
-
2 года назад
134 2 года назад 1:52Impact of prior BCMA-directed therapy on the efficacy of elranatamab in R/R multiple myeloma
-
4 года назад
334 4 года назад 8:13BCMA-targeted BiTEs for multiple myeloma
-
3 года назад
91 3 года назад 3:41Moving BCMA-targeted agents to the frontline setting in myeloma & sequencing immunotherapies